These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 16608420)

  • 21. Evidence of determinant spreading in the antibody responses to prostate cell surface antigens in patients immunized with prostate-specific antigen.
    Cavacini LA; Duval M; Eder JP; Posner MR
    Clin Cancer Res; 2002 Feb; 8(2):368-73. PubMed ID: 11839651
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vivo effects of vaccination with six-transmembrane epithelial antigen of the prostate: a candidate antigen for treating prostate cancer.
    Garcia-Hernandez Mde L; Gray A; Hubby B; Kast WM
    Cancer Res; 2007 Feb; 67(3):1344-51. PubMed ID: 17283172
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunological approaches for the treatment of prostate cancer.
    Slovin SF; Kelly WK; Scher HI
    Semin Urol Oncol; 1998 Feb; 16(1):53-9. PubMed ID: 9508084
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naïve prostate cancer.
    Simons JW; Carducci MA; Mikhak B; Lim M; Biedrzycki B; Borellini F; Clift SM; Hege KM; Ando DG; Piantadosi S; Mulligan R; Nelson WG
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3394-401. PubMed ID: 16740763
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Generation of robust cytotoxic T lymphocytes against prostate specific antigen by transduction of dendritic cells using protein and recombinant adeno-associated virus.
    Mahadevan M; Liu Y; You C; Luo R; You H; Mehta JL; Hermonat PL
    Cancer Immunol Immunother; 2007 Oct; 56(10):1615-24. PubMed ID: 17356843
    [TBL] [Abstract][Full Text] [Related]  

  • 26. DNA vaccination for prostate cancer.
    Roos AK; King A; Pisa P
    Methods Mol Biol; 2008; 423():463-72. PubMed ID: 18370222
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Increased frequency and responsiveness of PSA-specific T cells after allogeneic hematopoetic stem-cell transplantation.
    Uhlin M; Okas M; Karlsson H; Gertow J; Henningsohn L; Ringdén O; Kärre K; Levitsky V; Mattsson J
    Transplantation; 2009 Feb; 87(4):467-72. PubMed ID: 19307781
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Allogeneic retrovirally transduced, IL-2- and IFN-gamma-secreting cancer cell vaccine in patients with hormone refractory prostate cancer--a phase I clinical trial.
    Brill TH; Kübler HR; von Randenborgh H; Fend F; Pohla H; Breul J; Hartung R; Paul R; Schendel DJ; Gansbacher B
    J Gene Med; 2007 Jul; 9(7):547-60. PubMed ID: 17514769
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Improved efficacy of DNA vaccination against prostate carcinoma by boosting with recombinant protein vaccine and by introduction of a novel adjuvant epitope.
    Lu Y; Ouyang K; Fang J; Zhang H; Wu G; Ma Y; Zhang Y; Hu X; Jin L; Cao R; Fan H; Li T; Liu J
    Vaccine; 2009 Aug; 27(39):5411-8. PubMed ID: 19616501
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Technology Insight: vaccine therapy for prostate cancer.
    Vieweg J; Dannull J
    Nat Clin Pract Urol; 2005 Jan; 2(1):44-51. PubMed ID: 16474576
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Decreased cytotoxic T cell activity generated by co-administration of PSA vaccine and CpG ODN is associated with increased tumor protection in a mouse model of prostate cancer.
    Lubaroff DM; Karan D; Andrews MP; Acosta A; Abouassaly C; Sharma M; Krieg AM
    Vaccine; 2006 Aug; 24(35-36):6155-62. PubMed ID: 16876291
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Therapeutic vaccines for prostate cancer.
    Cha E; Fong L
    Curr Opin Mol Ther; 2010 Feb; 12(1):77-85. PubMed ID: 20140819
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dendritic cell vaccines for the treatment of prostate cancer.
    Lehrfeld TJ; Lee DI
    Urol Oncol; 2008; 26(6):576-80. PubMed ID: 18996314
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunotherapeutics in development for prostate cancer.
    Harzstark AL; Small EJ
    Oncologist; 2009 Apr; 14(4):391-8. PubMed ID: 19342474
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tumor-related immunity in prostate cancer patients treated with human recombinant granulocyte monocyte-colony stimulating factor (GM-CSF).
    Schwaab T; Tretter CP; Gibson JJ; Cole BF; Schned AR; Harris R; Fisher JL; Crosby N; Stempkowski LM; Heaney JA; Ernstoff MS
    Prostate; 2006 May; 66(6):667-74. PubMed ID: 16425182
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vaccine therapy for prostate cancer.
    Sonpavde G; Spencer DM; Slawin KM
    Urol Oncol; 2007; 25(6):451-9. PubMed ID: 18047951
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prostate cancer immunotherapy.
    McNeel DG
    Curr Opin Urol; 2007 May; 17(3):175-81. PubMed ID: 17414515
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synergistic antitumor effect of chemotactic-prostate tumor-associated antigen gene-modified tumor cell vaccine and anti-CTLA-4 mAb in murine tumor model.
    Li N; Qin H; Li X; Zhou C; Wang D; Ma W; Lin C; Zhang Y; Wang S; Zhang S
    Immunol Lett; 2007 Nov; 113(2):90-8. PubMed ID: 17913245
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prostate stem cell antigen vaccination induces a long-term protective immune response against prostate cancer in the absence of autoimmunity.
    Garcia-Hernandez Mde L; Gray A; Hubby B; Klinger OJ; Kast WM
    Cancer Res; 2008 Feb; 68(3):861-9. PubMed ID: 18245488
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pox viral vaccine approaches.
    Arlen PM; Kaufman HL; DiPaola RS
    Semin Oncol; 2005 Dec; 32(6):549-55. PubMed ID: 16338420
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.